Philip Seeman

Philip Seeman
Born February 8, 1934
Winnipeg, Manitoba
Awards Order of Canada

Philip Seeman, OC FRSC (born February 8, 1934) is a Canadian schizophrenia researcher and neuropharmacologist, known for his research on dopamine receptors.

Born in Winnipeg, Manitoba, Seeman was raised in Montreal. He received a Bachelor of Science degree, honours Physics & Physiology (1955), a Master of Science degree, Physiology of Transport & Secretion (1956), and a Doctor of Medicine (1960) from McGill University. In 1966, he received a Ph.D. in Life Sciences from Rockefeller University.

In 1967, Seeman became an Assistant Professor in the Department of Pharmacology at the University of Toronto. In 1970, he was appointed a Professor.

In 1974, having spent years in search for the binding site of antipsychotic medication, he discovered the dopamine D2 receptor, the basis for the dopamine hypothesis of schizophrenia.[1][2]

In 2001, he was made an Officer of the Order of Canada "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".[3] In 1985, he was made a Fellow of the Royal Society of Canada.[4]

Notes

  1. ↑ P. Seeman, M. Chau-Wong, J. Tedesco & K. Wong (November 1975). "Brain receptors for antipsychotic drugs and dopamine: direct binding assays". Proceedings of the National Academy of Sciences of the United States of America 72 (11): 4376–4370. doi:10.1073/pnas.72.11.4376. PMC 388724. PMID 1060115.
  2. ↑ "People". CMAJ 151 (8): 1186–1187. 1994. PMC 1337253.
  3. ↑ Order of Canada citation
  4. ↑ http://www.sciandmed.com/sm/journalviewer.aspx?issue=1066&article=787&action=1

References

  • Madras, B.K. (2013). "History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia". Journal of the History of the Neurosciences: Basic and Clinical Perspectives 22 (1): 62–78. doi:10.1080/0964704x.2012.678199.
  • Seeman, P. (2011). "All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors". CNS Neuroscience and Therapeutics 17 (2): 118–132. doi:10.1111/j.1755-5949.2010.00162.x.
  • P. Seeman (2010). "Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clinical Schizophrenia & Related Psychoses April: 56-73.
  • P. Seeman (2007), Scholarpedia, 2(10): 3634 doi.4249/scholarpedia.3634
  • Seeman, P. (2006). "Targeting the dopamine D2 receptor in schizophrenia". Expert Opinion on Therapeutic Targets 10: 515–531. doi:10.1517/14728222.10.4.515.
  • Seeman, P.; Weinshenker, D.; Quirion, R.; Srivastava, L.; Bhardwaj, S.K.; Grandy, D.K.; Premont, R.; Sotnikova, T.; Boksa, P.; El-Ghundi, M.; O'Dowd, B.F.; George, S.R.; Perreault, M.L.; Mannisto, P.T.; Robinson, S.; Palmiter, R.D.; Tallerico, T. (2005). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis". Proceedings National Academy of Sciences, U.S.A. 102: 3513–3518. doi:10.1073/pnas.0409766102.
  • Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. (1975). "Brain receptors for antipsychotic drugs and dopamine: Direct binding assays". Proceedings of the National Academy of Sciences, USA 72: 4376–4380. doi:10.1073/pnas.72.11.4376.

External links